XVIVO Perfusion AB publishes its interim financial report covering the first nine months of 2026. The company, specializing in perfusion technologies for organ preservation, provides updates on its operations and performance metrics. The report aligns with its focus on medical devices for extending organ viability outside the body.
XVIVO Perfusion AB’s nomination committee comprises shareholders holding **29.62% of total shares** as of **August 31, 2026**. The committee is responsible for proposing candidates for board elections. XVIVO Perfusion develops perfusion systems for organ preservation and transplantation.
XVIVO submits a Premarket Approval (PMA) application to the FDA for its **Heart Assist Transport System**, backed by clinical data from the **PRESERVE IDE trial**. The device aims to support patients during transport by maintaining organ perfusion outside the body. XVIVO cites additional evidence from the ongoing **PRESERVE** study to strengthen its submission.
XVIVO says its Heart Assist Transport system received CE certificates. The certificates make the heart preservation technology available to heart transplant centers across Europe.
